Cannabidiol (CBD) has attracted increasing interest due to its therapeutic potential for treating numerous diseases. However, CBD is very lipophilic and has very unfavorable pharmacokinetics and low bioavailability. Efforts are focused on developing drug delivery systems for enhanced solubilization and therapeutic activity of CBD. Here, we report the preparation of original super-macroporous cryogels from 2-hydroxyethyl cellulose (HEC) and β-cyclodextrin (β-CD) designed for the topical delivery of CBD. The cryogels were synthesized by photochemical crosslinking in a frozen aqueous system, purified, and then loaded with CBD. The effect of HEC/β-CD mass ratio (100:0; 50:50; 40:60 and 20:80) in the reaction mixture on the reaction efficiency, physico-mechanical properties of cryogels, drug release profile, and antineoplastic potential were evaluated in detail. The cryogels showed a bi-phasic release behavior: initial burst release in the first 3 hours followed by slower drug release which can be beneficial in the treatment of cutaneous neoplastic diseases.

Aripiprazole is a second‐generation atypical antipsychotic used for the treatment of schizophrenia, bipolar disorder, tic disorders, major depressive disorder, etc. However, aripiprazole is poorly soluble in water and many efforts are focused on developing delivery systems which can improve the solubility and the therapeutic activity of aripiprazole. In this contribution, the fabrication of novel cryogel carriers comprising β‐cyclodextrin (β‐CD) moieties for improved solubilization of aripiprazole is reported. Cryogels are synthesized by photochemical crosslinking of N,N‐dimethylacrylamide (DMA) and β‐CD triacrylate (β‐CD‐Ac3) in frozen aqueous system using H2O2 as initiator. The effect of DMA/β‐CD‐Ac3 mass ratio on the reaction efficiency, physico‐mechanical properties of cryogel, and drug loading efficiency is evaluated. The cryogel carriers are loaded with aripiprazole via procedure favoring inclusion of drug molecules into the hydrophobic cavity of β‐CD. The release of aripiprazole from PDMA/β‐CD carriers at pH 1.2 and 6.8 is studied and compared to the pure PDMA carriers.